ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Swiss firm Bachem says it will spend about $760 million to build a third peptide and oligonucleotide plant in Switzerland. The company says it expects to employ more than 500 people at the new site, in Sisslerfeld, by 2030. Bachem is in the process of spending about $560 million to expand its facility in Bubendorf, Switzerland. According to the firm, the large investments are a response to growth in peptides and oligonucleotides as active pharmaceutical ingredients.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X